About the session

Measurable residual disease (MRD) is the most important post-treatment predictor of outcome in patients with adult myeloid leukemia (AML). While flow cytometry-based methods for MRD detection are well-established clinically, molecular methods of MRD detection are still in research development. The use of digital PCR for highly sensitive monitoring of AML-associated mutations in patients on a variety of treatment plans will be discussed, as well as its predictive value for relapse. Bone marrow and cell-free DNA-based MRD will be explored. We will also  demonstrate the value of multiplexing assays for simultaneous detection of multiple mutations in limiting patient samples.


Amanda C. Winters
University of Colorado, USA.
Dr. Amanda Winters is an Assistant Professor of Pediatrics at the University of Colorado and Children's Hospital Colorado. As a clinician, she treats children and adolescents diagnosed with leukemias and lymphomas. Her primary research focuses on developing high-sensitivity mutation-based measurable residual disease assays for children and adults with acute myeloid leukemia. She is also interested in preclinical validation of candidate targeted therapies to improve outcomes in pediatric AML.